Seleccionar página

However, trailing PE ratios do not factor in the company’s projected growth rate, resulting in many newer firms having high PE ratios due to high growth potential enticing investors despite inadequate earnings. Biogen Inc receives a strong valuation ranking of 96 from InvestorsObserver data analysis. The proprietary ranking system focuses on the underlying health of a company through analysis of its stock BIIB stock forecast price, earnings, and growth rate. BIIB has a better value than 96% of stocks based on these valuation analytics. Investors primarily focused on buy-and-hold strategies will find the valuation ranking relevant to their goals when making investment decisions. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock’s expected earnings growth rate.

  • For example, if BIIB is testing support buy signals surface, and resistance is the target.
  • Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.
  • It offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis,…
  • On average, Wall Street analysts predict that Biogen’s share price could reach $282.33 by Oct 24, 2023.
  • At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors.

Meanwhile, our latest consensus estimate is calling for revenue of $2.47 billion, down 11.1% from the prior-year quarter. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements. Or is there an opportunity to expand the business’ product line in the future? If investors know Biogen will grow in the future, the company’s valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biogen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Where Biogen Stands With Analysts

Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Biogen’s financial leverage. It provides some insight into what part of Biogen’s total assets is financed by creditors. Biogen’s bond ratings measure its overall creditworthiness, which in many ways corresponds to the cost of borrowing for Forex news an issuer. These ratings assign a letter grade to all of Biogen’s outstanding corporate bonds that indicate their credit quality. We use reports published by private self-sufficient rating services such as Standard & Poor’s or Fitch Ratings Inc. to evaluate a bond issuer’s financial strength or its ability to pay a bond’s principal and interest. It is an academic score to determine the current strength of Biogen Inc financial position.

Biogen Inc stock

Following the failure of Aduhelm, Biogen announced a set of near-term operational priorities to drive renewed growth and value creation over time. Following the guidance increase, shares rose 1.3% in pre-market trading. Picking the right benchmark for Biogen stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Biogen stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Biogen is critical whether you are bullish or bearish towards Biogen Inc at a given time.

Biogen’s MS revenues were $1.62 billion in the reporter quarter, including Roche-partnered Ocrevus royalties, which declined 11% on a reported basis and 9% on a constant currency basis year over year. The reported revenue figures beat our model’s estimate of $1.60 billion. Free Report) Ocrevus were $281.9 million in the quarter, up 6.4% year over year.


We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive. These wide- and narrow-moat stocks have suffered losses lately and are now trading in 4- and 5-star range. U.S. ETFs collected modest inflows as stocks and bonds sold off last month. There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Biogen (BIIB – Research Report) and Zymeworks (ZYME – Research Report) with bullish sentiments. There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Biogen (BIIB – Research Report) and Taysha Gene Therapies (TSHA – Research Report) with bullish sentiments.

Earnings of Morphic beat estimates in three of the last four quarters and missed the mark just once, witnessing a surprise of 48.29%, on average. In the last reported quarter, MORF delivered an earnings surprise of 183.95%. In the past 60 days, estimates for Morphic’s 2023 loss per share have narrowed from $3.77 to $3.61 during the same period. Earnings of Codiak BioSciences beat estimates in dotbig three of the last four quarters and missed the mark just once, witnessing a surprise of 35.40% on average. In the last reported quarter, CDAK delivered an earnings surprise of 61.54%. In the past 60 days, estimates for Codiak BioSciences’ 2022 loss per share have narrowed from $1.94 to $1.81. During the same period, the loss estimates per share for 2023 have narrowed from $2.14 to $1.53.

Biogen Beats Revenue Expectations In The Third Quarter

It has a portfolio of medicines to treat multiple sclerosis , spinal muscular atrophy and Alzheimer’s disease. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA… Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA. Our tools can tell you how much better you can do entering a position in Biogen without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios.

Related Stocks

The board of directors generally takes responsibility for the Biogen’s affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors’ meetings. To pass a resolution, a majority of Biogen’s board members dotbig must vote for the resolution. The Biogen board of directors’ duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws. Over the last 2 years, BIIB has beaten EPS estimates 75% of the time and has beaten revenue estimates 100% of the time. Our experts picked 7 Zacks Rank #1 Strong Buy stocks with the best chance to skyrocket within the next days.

The most common way to measure the risk of Biogen is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Biogen. The Shape ratio is calculated by using BIIB stock price standard deviation and excess return to determine reward per unit of risk. To understand how volatile Biogen Inc is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S.

Latest On Biogen Inc

When running Biogen Inc price analysis, check to measure Biogen’s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biogen is operating at the current time. Most of Biogen’s value examination focuses on studying past and present price action to predict the probability of Biogen’s future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Biogen’s price. Additionally, you may evaluate how the addition of Biogen to your portfolios can decrease your overall portfolio volatility. The danger of trading Biogen Inc is mainly related to its market volatility and company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading.

Shares of Codiak BioSciences have lost 94.3% in the year-to-date period. Tecfidera sales declined 32.0% to $339.0 million in the quarter as multiple generic products have been launched in the United States. Outside U.S. revenues fell 22.8% to $246.5 million, hurt by pricing pressure.